Posted on 2/11/21
Cyteir Therapeutics Secures $80 Million in Series C
Cyteir Therapeutics, a leader in the discovery and development of next-generation synthetic lethal therapies for cancer, today announced the close of an oversubscribed $80 million Series . . .
Posted on 2/11/21
Pulmatrix Announces $40 Million Registered Direct Offering
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today . . .
Posted on 2/11/21
Signify Health Prices of IPO
DALLAS & NORWALK, Conn.--(BUSINESS WIRE)--Signify Health, Inc. a leading value-based healthcare platform enabled by advanced analytics, technology and nationwide healthcare networks, today announced the pricing of . . .
Posted on 2/11/21
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended . . .
Posted on 2/11/21
BIONIK Laboratories Reports Fiscal 2021 Q3 Financial Results
TORONTO & BOSTON--(BUSINESS WIRE)--BIONIK Laboratories Corp. (OTCQB:BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from . . .
Posted on 2/11/21
AlloVir Reports Full Year 2020 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today provided a corporate update and reported full-year 2020 financial results for the period ended . . .
Posted on 2/11/21
Genocea Provides Fourth Quarter 2020 Corporate Update
CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today provided a business update for . . .
Posted on 2/11/21
Acorda Therapeutics Sale of Manufacturing Operations to Catalent
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has completed the sale of its manufacturing operations in Chelsea, Massachusetts to Catalent. Under the . . .
Posted on 2/11/21
Is Moderna Stock Overvalued?
Moderna(NASDAQ:MRNA) stock skyrocketed last year. Its momentum has carried over into 2021 as well. After its tremendous gains, the biotech's market cap is now well over . . .
Posted on 2/11/21
Can KalVista Pharmaceuticals Stock Fly Higher?
The biotech industry's a wonky place where the outlook for a company's future can, and often does, change overnight. Successful clinical trial results for a potential . . .
Posted on 2/11/21
Bioasis Announces Shares for Debt Transaction
NEW HAVEN, Conn., Feb. 10, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology . . .
Posted on 2/11/21
Rhythm Pharmaceuticals Closes $172.5M Public Offering
BOSTON, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare . . .
Posted on 2/11/21
Sensei Biotherapeutics Closes IPO
BOSTON and ROCKVILLE, Md., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation . . .
Posted on 2/11/21
KalVista Pharmaceuticals Prices Upsized $193.5M Public Offering of Common Stock
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the pricing of its upsized underwritten public offering of 5,375,000 shares of its common . . .
Posted on 2/10/21
Stealth BioTherapeutics Prices Of $4.7 Million Registered Direct Offering Of American Depositary Shares
Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced . . .
Posted on 2/10/21
Biogen Announces the Pricing Terms of its Cash Tender Offer
CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the pricing terms of its previously announced offer to purchase for cash . . .
Posted on 2/10/21
Entity Vor Biopharma Closes $200M IPO
BOSTON--(BUSINESS WIRE)--PureTech Health plc (LSE: PRTC, Nasdaq: PRTC), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased . . .
Posted on 2/10/21
2021's States with the Best & Worst Dental Health - WalletHub Study
With February being National Children’s Dental Health Month and the CDC reporting no COVID-19 transmissions in a clinical dental setting, the personal-finance website WalletHub today released . . .
Posted on 2/10/21
Can COVID Vaccine Latecomer Ocugen Beat Pfizer and Moderna?
Several days ago, Ocugen (NASDAQ:OCGN) was an early-stage biotech company focusing on gene therapy to cure eye diseases. And then everything changed. All of a sudden, . . .
Posted on 2/10/21
Why Collegium Pharmaceutical Rose Nearly 10% on Tuesday
What happenedAt times, the reason or reasons behind a stock's rise are obscure or mysterious. But that certainly wasn't the case with Collegium Pharmaceutical (NASDAQ:COLL) on . . .
Posted on 2/10/21
Oncorus Proposes Public Offering of Common Stock
CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation, systemically active viral immunotherapies to transform outcomes . . .
Posted on 2/10/21
Vor Biopharma Closes Over $200M IPO
CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted . . .
Posted on 2/10/21
KalVista Pharmaceuticals Proposes Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) announced today that it intends to offer and sell 4,500,000 shares of its common stock in an underwritten public . . .
Posted on 2/9/21
Quanterix Closes Public Offering Including Exercise of Underwriters’ Option
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced the closing of its previously announced . . .
Posted on 2/8/21
Akebia Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release . . .
Boston
